ST. LOUIS, June 28, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of gene editing and personalized medicine technologies, announced today that it has launched a service for high throughput gene expression analysis. Based on the NanoString nCounter platform, the service works with a large array of sample types, including formats such as formalin-fixed […]
Read more
Canopy Biosciences signs agreement with Cosmo Bio to sell gene engineering products in Japan ST. LOUIS, June 22, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC (“Canopy Biosciences”), an emerging provider of gene editing and personalized medicine technologies, announced a distributor agreement with Cosmo Bio Co., Ltd. (“Cosmo Bio”) for its TUNR Flexible Gene Editing technology in […]
ST. LOUIS, March 31, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of products and services for gene editing and personalized medicine, announced today that it has entered an exclusive licensing agreement with Washington University in St. Louis and Johns Hopkins for key intellectual property around a novel technology for gene editing. The TUNRTM […]
“The rap on St. Louis’ biotech industry is that all of its startups are years away from selling products, with no big success stories yet. Don’t tell that to Ed Weinstein, co-founder and chief executive of Canopy Biosciences. Canopy is launching its first product just months after being founded, and it expects to quickly achieve […]
iGTRCN reviews a recent paper by Sergej Djuranovic’s lab at Washington University in St. Louis detailing the technology at the heart of our TUNR system. Read the entire iGTRCN article
Canopy featured in the St. Louis Business Journal! Read all about us here. “Canopy Biosciences, a young startup looking to accelerate the commercialization of life science reagent tools and services, has raised $2 million from investors.” Canopy looks to in-license — essentially a collaboration agreement between two parties in which one company performs the R&D […]
Full speed. Half speed. Full stop. Those are the usual choices for controlling the amount of protein produced from a particular gene. Other speeds are possible, but they typically require a lot of effort on the part of scientists, who often resort to the identification and exploitation of a hypomorphic mutation, that is, a mutation […]
